Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Recent R&D Highlights

    • 6 Accesses

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      Source: R&D Insight, Adis International

    2. 2.

      Intercell will be profiled in an upcoming issue of Pharmaceutical & Diagnostic Innovation.

    3. 3.

      Source: R&D Insight, Adis International.

    4. 4.

      American Association of Cancer Researchers (AACR), US National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC).

    References

    1. 1.

      European Biotechnology. Intercell. Acambis JE trial start does not lead us to change numbers. New York: Lehman Brothers Global Equity Research, 2005

    2. 2.

      Acambis. Acambis achieves major milestone in JE vaccine development with start of pivotal phase lll clinical testing Media release: 15 Nov 2005

    3. 3.

      Novartis. Exjade, a breakthrough once-daily oral iron chelator, receives first approval worldwide in the US. Media release: 3 Nov 2005

    4. 4.

      European Pharmaceuticals. Novartis. Operating results. 3Q05 results & Hexal/Eon integration New York: Lehman Brothers Global Equity Research, 2005

    5. 5.

      SciWords. Phenoxodiol produces anti-cancer responses in women with cervical cancer. Media release: 17 Nov 2005

    6. 6.

      SciWords. Phenoxodiol delays tumor progression in hormone refractory prostate cancer. Media release: 17 Nov 2005-11-21

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 3, 17–19 (2005). https://doi.org/10.1007/BF03257014

    Download citation